Incidental splenic masses found during abdominal CT scan are rarely malignant, may not need follow-up.
Follow-up of incidental splenic masses noted during abdominal CT may not be indicated, according to a study published in the journal Radiology.
Researchers from Beth Israel Deaconess Medical Center in Boston, Mass., performed a retrospective study to evaluate whether an incidentally noted splenic mass at abdominal CT require further imaging work-up.
The researchers reviewed images, follow-up examinations, and electronic medical records of 379 patients with splenic masses detected during abdominal CT examinations; 214 (56.5 percent) were women and 165 (43.5 percent) men, mean age of 59.3 years. The patients were divided into three groups:
• Group 1: 145 (38.3 percent) patients with a history of malignancy
• Group 2: 29 (7.6 percent) patients with symptoms such as weight loss, fever, or pain related to the left upper quadrant and epigastrium
• Group 3: 205 (54.1 percent) patients with incidental findings
The final diagnoses of the causes of the masses were confirmed with imaging follow-up (83.9 percent), clinical follow-up (13.7 percent), and pathologic examination (2.4 percent).
The results showed the incidence of malignant splenic masses was 49 of 145 (33.8 percent) in the malignancy group, eight of 29 (27.6 percent) in the symptomatic group, and two of 205 (1 percent) in the incidental group. The incidental group consisted of new diagnoses of lymphoma in one (50 percent) patient and metastases from ovarian carcinoma in one (50 percent) patient. Malignant splenic masses in the incidental group were not indeterminate, because synchronous tumors in other organs were diagnostic of malignancy.
The researchers concluded that with an incidental splenic mass, the likelihood of malignancy is very low (1 percent) and follow-up of incidental splenic masses may not be indicated.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.